No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARQT Arcutis Biotherapeutics
- 8.740
- -0.200-2.24%
Close Apr 23 16:00 ET
- 8.809
- +0.069+0.79%
Post 19:08 ET
984.15MMarket Cap-2312P/E (TTM)
9.295High8.720Low1.60MVolume9.020Open8.940Pre Close14.23MTurnover1.85%Turnover RatioLossP/E (Static)112.60MShares15.21052wk High11.11P/B755.57MFloat Cap1.76052wk Low--Dividend TTM86.45MShs Float40.880Historical High--Div YieldTTM6.43%Amplitude1.760Historical Low8.916Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
Express News | Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $16 Price Target
Arcutis Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 34.57% Needham → $16 Reiterates Buy → Buy 02/28/2024 -7.49% Goldman Sachs $6 → $11 Maintains Ne
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics Welcomes New CFO David Topper
Arcutis Biotherapeutics Appoints CFO
Comments
Arcutis' CEO, Frank Watanabe, commends Todd Tucker's promotion to CHRO, praising his leadership in people-centered programs. Tucker's leadership is expected to boost the company's growth and workforce productivity.
Press Release: Arcutis Promotes Todd Tucker to Chief Human Resources Officer 1
Hmm?
$Arcutis Biotherapeutics(ARQT.US$ Ive posted lots of great news here! Especially since early/mid December! And with the exception of a few, the chat is dead! Which is kinda surprising considering the massive increase in price overall from my December 15/17 post! Is it because so many are enjoying the slow but super untrend and dont want to bring attention to the massive gains! Hehehe. Or did not many actually join in? Hehehe! Just thinking outloud! 
1
4
Despite strong revenue growth, the company's P/S ratio remains stagnant, possibly due to waning performance expectations. Its shares have risen, aligning the P/S with industry median. However, its subdued growth projections compared to the industry make its current P/S ratio surprising. Predicted revenues may not sustain positive sentiment, risking shareholders' investments and potential investors paying a premium.
ColumnsDon't Just Focus on AI! Biotech Stocks Are Rallying
Since the beginning of this year, $NVIDIA(NVDA.US$ has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...
58
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg